Related Experiment Videos
Cytoprotection in acute myelogenous leukemia (AML) therapy
Dolores Grosso1, Joanne Filicko, Guillermo Garcia-Manero
1Thomas Jefferson Health System, Blood and Marrow Transplant Program, Philadelphia, PA 19107, USA. l_grosso@lac.jci.tju.edu
Seminars in Oncology
|February 24, 2005
Summary
Adding amifostine to the "7 + 3" regimen for acute myelogenous leukemia (AML) allows for higher idarubicin doses without increased side effects. This approach offers a more intensive yet tolerable treatment for AML patients of all ages.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- Acute myelogenous leukemia (AML) treatment is challenging due to disease heterogeneity and patient age.
- Poor-risk cytogenetics and older age ( > 55-60 years) are associated with lower complete remission rates in AML.
- Intensive chemotherapy for older AML patients can be poorly tolerated.
Purpose of the Study:
- To develop a maximally intensive yet tolerable induction therapy for acute myelogenous leukemia (AML).
- To evaluate the safety and feasibility of escalating idarubicin doses in the "7 + 3" regimen with amifostine in AML patients.
Main Methods:
- A Phase I study involving 33 AML patients.
- Administration of amifostine (cytoprotective agent) before each idarubicin infusion.
- Dose escalation of idarubicin within the "7 + 3" regimen up to a maximum of 24 mg/m².
Main Results:
- Amifostine enabled a substantial escalation of idarubicin dose up to 21 mg/m².
- No significant increase in side effects was observed with the escalated idarubicin doses.
- The modified regimen demonstrated potential for both intensity and broad applicability across age groups.
Conclusions:
- The addition of amifostine to the "7 + 3" regimen allows for safe dose escalation of idarubicin in AML induction therapy.
- This approach provides an intensive treatment option suitable for AML patients irrespective of age.
- Further Phase II studies are underway to confirm the efficacy of this enhanced regimen.